NCT00080925View on ClinicalTrials.gov

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Study Completion Date

December 31, 2010

Conditions

Chronic Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms

Interventions

BIOLOGICAL

filgrastim

BIOLOGICAL

graft-versus-tumor induction therapy

BIOLOGICAL

rituximab

BIOLOGICAL

therapeutic allogeneic lymphocytes

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

cytarabine

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

fludarabine phosphate

DRUG

prednisone

DRUG

vincristine sulfate

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (1)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00080925 - T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies | Biotech Hunter | Biotech Hunter